Upcoming Deadline for Capricor Therapeutics Securities Fraud Class Action Lawsuit

Critical Update for Capricor Therapeutics Shareholders

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently entangled in a significant securities fraud class action lawsuit. The Gross Law Firm has issued urgent advice to shareholders who purchased shares during the designated class period. This lawsuit highlights critical allegations regarding the company’s handling of its lead therapy candidate, deramiocel, which was intended for treating cardiomyopathy related to Duchenne muscular dystrophy (DMD).

Understanding the Lawsuit

According to the complaint filed, defendants allegedly provided misleading and materially incomplete information to investors concerning deramiocel’s prospects. Although they expressed confidence in securing a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA), they simultaneously withheld adverse details about the drug's safety and efficacy data from its Phase 2 HOPE-2 trial study. This secrecy led to false expectations among investors.

On July 11, 2025, just after the class period ended, Capricor announced receiving a Complete Response Letter (CRL) from the FDA. The CRL explicitly stated that the company did not meet the necessary criteria for substantial evidence of the drug's effectiveness, prompting an immediate and drastic decline in the company’s stock price—from $11.40 per share to $7.64 per share within a day.

Key Dates and Next Steps

For shareholders who believe they may have been affected, it is essential to act swiftly. The deadline to register for participation in this class action and potentially become a lead plaintiff is September 15, 2025. However, it’s important to note that one does not need to be appointed as a lead plaintiff to benefit from a recovery in this case.

Upon registration, shareholders will gain access to a portfolio monitoring feature that keeps them updated on any developments related to the lawsuit. Shareholders can register their information through the prescribed link provided by The Gross Law Firm.

Register Here for More Information

Why Choose The Gross Law Firm?

The Gross Law Firm is a reputable national class action firm dedicated to protecting investor rights against fraudulent practices and deceit. With a commitment to promoting responsible business conduct, the firm seeks to ensure companies are held accountable for actions that mislead investors and inflate stock prices artificially.

If you have suffered losses due to this alleged misconduct, engaging with The Gross Law Firm could be a pivotal step.

For more details, shareholders are encouraged to reach out directly:
Contact Information:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Don't delay—act now to safeguard your rights as a shareholder in Capricor Therapeutics.